CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
In vivo treatment with nanolipid-formulated siRNAs targeting ISG15 leads to enhanced responsiveness to interferon in primary hepatocytes
DOI 10.1055/s-0031-1295928
Bibliografische Angaben
Nachweis in CareLit
Autor:innenCI Real, R Bröring, M John, K Jahn-Hofmann, L Ickenstein, K Kleinehr, G Gerken, JF Schlaak
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2012
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Non-response of HCV patients to combination therapy has previously been associated with a strong up-regulation of the interferon stimulated gene 15 (ISG15). The ISG15 gene product is a pro-viral factor for HCV replication in hepatocytes, but not in non-parenchymal liver cells (NPC). RNAi-based suppression of ISG15 expression in hepatocytes may overcome non-response to standard combination treatment. Me…
Zitieren
Zitierempfehlung
CI Real, R Bröring, M John, K Jahn-Hofmann, L Ickenstein, K Kleinehr, G Gerken, JF Schlaak (2012) In vivo treatment with nanolipid-formulated siRNAs targeting ISG15 leads to enhanced responsiveness to interferon in primary hepatocytes. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0031-1295928
Mit CareLit weiterarbeiten